The Changing Landscape of NASH: Navigating Current and Emerging Approaches in Diagnosis and Treatment


Live Webinar


Monday, November 4, 2019 6:00 - 7:15 pm EST


This educational activity is supported by an independent medical educational grant from Intercept Pharmaceuticals.


This activity is designed for US-based endocrinologists, cardiologists, lipidologists, diabetologists, gastroenterologists, hepatologists, PAs, registered nurses, and NPs


The increasing rates of obesity, diabetes, and metabolic syndrome in the United States are leading to more cases of non-alcoholic fatty liver disease (NAFLD) and its most aggressive subtype, non-alcoholic steatohepatitis (NASH), With are now being encountered at a greater frequency in clinical practice. NASH can lead to significant morbidity and mortality, including liver fibrosis, cirrhosis, and hepatocellular carcinoma (HCC)—in fact, HCC caused by NASH is now the second leading cause of liver transplants in the US and poised to become the leading cause of liver transplants by 2020.

Thus, clinicians in several therapeutic areas may treat or possibly encounter patients with diagnosed or undiagnosed NASH, and being aware of this disease is crucial for the early recognition, diagnosis and management in order to improve outcomes. NASH, described as the hepatic manifestation of metabolic syndrome, remains challenging to diagnose and treat, but significant advances have been made in the recent years. This activity will discuss the increasing prevalence and clinical significance of NASH, current and emerging diagnostic methods, what can be done now to manage it, and emerging treatment options that are in advanced clinical development.


After completing this activity, the participant should be better able to:

  • Review the pathogenesis of NAFLD and NASH
  • Identify current and emerging approaches and tools to diagnose NAFLD and NASH in clinical practice
  • Utilize the current guidelines and recommendations for treatment of NAFLD and NASH in order to optimize patient management
  • List emerging pharmacotherapies that aim to target various metabolic, inflammatory, and fibrotic pathways involved in disease progression


Kenneth Cusi

Kenneth Cusi, MD, FACP, FACE
Professor of Medicine
Staff, Malcom Randall VAMC
Chief, Division of Endocrinology, Diabetes and Metabolism The University of Florida
Gainesville, FL


I. Welcome and Introductions 6:00 - 6:05 pm
II. Pathophysiology, epidemiology, NAFLD/NASH Progression 6:05 - 6:15 pm
III. Current and Emerging Diagnostic Approaches 6:15 - 6:30 pm
IV. Current and Emerging Treatments 6:30 - 6:50 pm
V. Patient Case Discussion 6:50 - 7:05 pm
VI. Conclusions and Audience Q&A 7:05 - 7:15 pm


In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and CMHC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.


The Postgraduate Institute for Medicine designates this live activity for a maximum of 1.25 AMA PRA Category 1 Credits™ Physicians should claim only the credit commensurate with the extent of their participation in the activity.


The maximum number of hours awarded for this Continuing Nursing Education activity is 1.2 contact hours. Pharmacotherapy contact hours for Advanced Practice Registered Nurses will be designated on your certificate.


Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COO they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Dr. Cusi discloses the following:
Consulting Fees: BHS,Cirius, Novo, Merck, Janssen, Lilly, Pfizer, Genentech
Contracted Research: Poxel, Inventive, Zydus, Echosens, Lilly, Cirius, Novartis, Novo

Planners and Managers
The PIM planners and managers have nothing to disclose.
The CMHC planners and managers have nothing to disclose.


This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.


If you wish to receive acknowledgment for completing this activity, please complete the evaluation on On the navigation menu, click on "Find Post-test/Evaluation by Course" and search by course ID 14688. Upon registering and completing the activity evaluation, your certificate will be made available immediately.


There is no registration fee for this educational activity.